Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ERNA Eterna Therapeutics Inc.

Market Closed 07-10 16:00:00 EDT

6.06

+0.13

+2.19%

盘后6.19

+0.13+2.15%

19:41 EDT

High6.20	Low5.78	Vol14.31K
Open6.13	D1 Closing5.93	Amplitude7.08%
Mkt Cap7.07M	Tradable Cap4.05M	Total Shares1.17M
T/O85.44K	T/O Rate2.14%	Tradable Shares668.70K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ERNA","market":"US","secType":"STK","nameCN":"Eterna Therapeutics Inc.","latestPrice":6.06,"timestamp":1783713600000,"preClose":5.93,"halted":0,"volume":14307,"hourTrading":{"tag":"盘后","latestPrice":6.19,"preClose":6.06,"latestTime":"19:41 EDT","volume":1121,"amount":6917.7987,"timestamp":1783726911768,"change":0.13,"changeRate":0.021452,"amplitude":0.021452},"delay":0,"changeRate":0.02192242833052275,"floatShares":668700,"shares":1166176,"eps":-30.4836,"marketStatus":"Market Closed","change":0.13,"latestTime":"07-10 16:00:00 EDT","open":6.13,"high":6.2,"low":5.78,"amount":85443.8547891,"amplitude":0.070826,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-30.4836,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"listingDate":465451200000,"exchange":"NASDAQ","adjPreClose":5.93,"preHourTrading":{"tag":"盘前","latestPrice":5.95,"preClose":5.93,"latestTime":"08:18 EDT","volume":33,"amount":196.35,"timestamp":1783685891861,"change":0.02,"changeRate":0.003373,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":6.19,"preClose":6.06,"latestTime":"19:41 EDT","volume":1121,"amount":6917.7987,"timestamp":1783726911768,"change":0.13,"changeRate":0.021452,"amplitude":0.021452},"volumeRatio":0.7501415618897382},"requestUrl":"/m/hq/s/ERNA/tweets","defaultTab":"tweets","newsList":[{"id":"2648337556","title":"Ernexa Therapeutics Holds Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2648337556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648337556?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:32","pubTimestamp":1783024364,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics holds annual shareholder meetingErnexa Therapeutics held its annual stockholder meeting on July 1, 2027.Stockholders elected five directors to serve until the 2027 annual meeting.A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL42FyvX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646497360","title":"Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2646497360","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646497360?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:31","pubTimestamp":1782505888,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics SVP of Finance Sandra Gurrola resigns effective July 3Ernexa Therapeutics’ SVP of Finance Sandra Gurrola resigned, effective July 3, 2026.Gurrola will provide part-time transition ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL7qNFjw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646058888","title":"Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2646058888","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646058888?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:15","pubTimestamp":1782393300,"startTime":"0","endTime":"0","summary":"New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability Inaugural vide","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317625/0/en/Ernexa-Therapeutics-Launches-CEO-Corner-to-Provide-Deeper-Insights-into-Company-Progress-Scientific-Strategy-and-Vision-for-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","BK4007","BK4139","BK4539","LENZ","ERNA","BK4097","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644749091","title":"Ernexa expects FDA review of ERNA-101 IND in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644749091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644749091?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:27","pubTimestamp":1781702848,"startTime":"0","endTime":"0","summary":"Ernexa set a Q3 2026 IND submission for ERNA-101, positioning the cell therapy for U.S. regulatory review.The company targets FDA review in Q4 2026, with a first-in-human Phase 1 study planned to start in the same quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL8yVRgk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644445746","title":"Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644445746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644445746?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:48","pubTimestamp":1781700487,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42O0UH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644749918","title":"Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2644749918","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644749918?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:47","pubTimestamp":1781700420,"startTime":"0","endTime":"0","summary":"Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313445/0/en/Ernexa-Therapeutics-Positioned-to-Become-a-Clinical-Stage-Biotechnology-Company-as-ERNA-101-On-Track-for-Planned-Q3-2026-IND-Submission-and-First-in-Human-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642946026","title":"Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642946026","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642946026?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:41","pubTimestamp":1781008860,"startTime":"0","endTime":"0","summary":"Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncologyAccess the segmenthere CAMBRIDGE, Mass., Ju","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308857/0/en/Ernexa-Therapeutics-Highlights-Ovarian-Cancer-Unmet-Need-Hope-for-Patients-and-Potential-Accessibility-Advantages-of-ERNA-101-in-Virtual-Investor-KOL-Connect-Segment-Featuring-Dr-I.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOPE","BK4211","ERNA","BK4139","KOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638867276","title":"Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2638867276","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638867276?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:06","pubTimestamp":1779890785,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced progress in the development of ERNA-101, the company’s therapeutic candidate, achieving multiple milestones th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-plans-erna-101-investigational-new-drug-submission-for-q3-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-plans-erna-101-investigational-new-drug-submission-for-q3-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638250065","title":"Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2638250065","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638250065?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:11","pubTimestamp":1779883860,"startTime":"0","endTime":"0","summary":"Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology companyCAMBRIDGE, Mass., May  27, 2026  (GLOBE NEWSWIRE) --","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301925/0/en/Ernexa-Therapeutics-Successfully-Completes-Key-Manufacturing-and-IND-Preparation-Milestones-for-ERNA-101-Toward-First-in-Human-Clinical-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636842404","title":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2636842404","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636842404?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:31","pubTimestamp":1779280260,"startTime":"0","endTime":"0","summary":"Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298486/0/en/Ernexa-Therapeutics-Releases-Virtual-Investor-KOL-Connect-Segment-Featuring-Dr-Elena-Ratner-Highlighting-Ovarian-Cancer-Landscape-and-ERNA-101-Opportunity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA","KOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635399390","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 12:42 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2635399390","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635399390?lang=en_us&edition=fundamental","pubTime":"2026-05-16 00:42","pubTimestamp":1778863378,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 12:42 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nAQN2LZ9P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634829217","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:38 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2634829217","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634829217?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:38","pubTimestamp":1778593137,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:38 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nAQN2LYMAX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634853253","title":"Ernexa Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2634853253","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634853253?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:11","pubTimestamp":1778533862,"startTime":"0","endTime":"0","summary":"Annual stockholder meeting set for July 1, 2026, held as virtual-only meeting via live audio webcast.Votes scheduled on electing five directors, ratifying Haskell & White LLP as independent registered public accounting firm for fiscal 2026.Ballot also includes adoption of 2026 Omnibus Equity Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL7ZgSX3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634325826","title":"Ernexa Q1 net loss narrows 32.87% to $5.51 million; no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2634325826","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634325826?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:03","pubTimestamp":1778533396,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics posted a net loss of USD 5.51 million for the quarter ended March 31, 2026, narrowing from USD 8.2 million a year earlier.Operating loss widened to USD 5.59 million from USD 2.73 million, driven by a USD 2.04 million goodwill impairment charge.Research and development expense climbed to USD 1.92 million from USD 1.31 million on higher ERNA-101 study fees, while general and administrative costs rose to USD 1.63 million from USD 1.42 million.Cash totaled about USD 9.2 million at March 31, 2026, and operating cash outflow was USD 2.26 million; net proceeds from a February public offering were about USD 9.5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content us","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL7GNBTm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284759","title":"Ernexa Therapeutics to join Virtual Investor Closing Bell event","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284759","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634284759?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:16","pubTimestamp":1778505414,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics to participate in Virtual Investor Closing Bell event on May 13, 2026 at 4:00 PM ET.Event to feature corporate overview from President and CEO Sanjeev Luther, with Chief Scientific Officer Robert Pierce discussing preclinical ovarian cancer results for ERNA-101, including complete tumor elimination and 100% survival in models when combined with PD-1 blockade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLJ8S7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","SG9999014005.SGD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","NDAQ","LU2210150020.SGD","BK4112","ERNA","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014013.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284706","title":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284706","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634284706?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:15","pubTimestamp":1778505300,"startTime":"0","endTime":"0","summary":"Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape Segment highlights significant unmet need in ovarian cancer and the potential of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291978/0/en/Ernexa-Therapeutics-Releases-Virtual-Investor-KOL-Connect-Segment-Highlighting-Ovarian-Cancer-Landscape-and-Lead-Candidate-ERNA-101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DBB","ERNA","KOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633087171","title":"Ernexa Therapeutics initiated with a Buy at Brookline","url":"https://stock-news.laohu8.com/highlight/detail?id=2633087171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633087171?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:58","pubTimestamp":1778191090,"startTime":"0","endTime":"0","summary":"Brookline initiated coverage of Ernexa Therapeutics (ERNA) with a Buy rating and $30 price target Ernexa is engineering induced pluripotent stem ce...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","LENZ","BK4211","BRKL","ERNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633195262","title":"Ernexa Therapeutics announces new ERNA-101 preclinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2633195262","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633195262?lang=en_us&edition=fundamental","pubTime":"2026-05-07 12:27","pubTimestamp":1778128039,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced new preclinical data demonstrating that its lead cell therapy candidate, ERNA-101, in combination with PD-1 bl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633139866","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2633139866","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633139866?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:34","pubTimestamp":1778074485,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nAQN2LXV0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633412133","title":"Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models","url":"https://stock-news.laohu8.com/highlight/detail?id=2633412133","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633412133?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:33","pubTimestamp":1778070839,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics on May 6, 2026 reported new preclinical results for lead cell therapy candidate ERNA-101 used with PD-1 blockade in ovarian cancer models; results were presented with this announcement.Combination treatment produced complete tumor elimination in tested models, outperforming either approach alone.Studies showed durable long-term survival in treated animals, supporting a potential curative profile in these models.Data point to tumor microenvironment remodeling that could make checkpoint inhibitors more effective in immunologically “cold” tumors.Program positioned to support a first-in-human study in advanced ovarian cancer, with additional combination work underway to broaden potential solid-tumor use.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL1T7bgP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","SG9999014039.USD","BK4112","BK4588","SG9999014005.SGD","ERNA","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","SG9999014013.SGD","BK4139","SG9999014021.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ernexatx.com","stockEarnings":[{"period":"1week","weight":-0.0335},{"period":"1month","weight":-0.0442},{"period":"3month","weight":0.2424},{"period":"6month","weight":-0.815},{"period":"1year","weight":-0.8776},{"period":"ytd","weight":-0.798}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.558824,"avgChangeRate":0.130666},{"month":2,"riseRate":0.382353,"avgChangeRate":-0.039626},{"month":3,"riseRate":0.558824,"avgChangeRate":0.018953},{"month":4,"riseRate":0.352941,"avgChangeRate":0.335049},{"month":5,"riseRate":0.411765,"avgChangeRate":0.015195},{"month":6,"riseRate":0.5,"avgChangeRate":0.005635},{"month":7,"riseRate":0.257143,"avgChangeRate":-0.034946},{"month":8,"riseRate":0.411765,"avgChangeRate":-0.028873},{"month":9,"riseRate":0.323529,"avgChangeRate":-0.027842},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.041231},{"month":11,"riseRate":0.5,"avgChangeRate":0.055021},{"month":12,"riseRate":0.323529,"avgChangeRate":-0.050712}],"exchange":"NASDAQ","name":"Eterna Therapeutics Inc.","nameEN":"Eterna Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eterna Therapeutics Inc.,ERNA,Eterna Therapeutics Inc.股票,Eterna Therapeutics Inc.股票老虎,Eterna Therapeutics Inc.股票老虎国际,Eterna Therapeutics Inc.行情,Eterna Therapeutics Inc.股票行情,Eterna Therapeutics Inc.股价,Eterna Therapeutics Inc.股市,Eterna Therapeutics Inc.股票价格,Eterna Therapeutics Inc.股票交易,Eterna Therapeutics Inc.股票购买,Eterna Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}